2 Best Biotech Stocks to Buy in September

With Washington once again looking at ways to negotiate lower prescription drug prices, the Health Care Select Sector SPDR Fund (NYSEMKT: XLV) is lagging the S&P 500 year to date, up 17% this year compared with the index's 21%.

Two of the top 10 holdings in the Health Care SPDR Fund are Merck (NYSE: MRK) and Pfizer (NYSE: PFE). Let's take a look at why these two stocks offer both value and safe dividend yields, and why income investors should consider buying them in September.

Image source: Getty Images.

Continue reading

Source Fool.com